03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
20:36 , May 12, 2017 |  BC Week In Review  |  Clinical News

Allergan completes enrollment in Phase III trials for AMD

Allergan plc (NYSE:AGN) completed enrollment of 1,800 total patients with wet age-related macular degeneration (AMD) in the Phase III CEDAR and SEQUOIA trials comparing abicipar pegol (AGN-150998, MP0112) vs. Lucentis ranibizumab. The double-blind, sham-controlled, international...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Clinical News

Abicipar pegol: Phase II data

The double-blind, sham-controlled, U.S. Phase II PALM trial in 151 DME patients showed that 1 mg intravitreal abicipar pegol every 8 weeks, 2 mg abicipar pegol every 8 weeks and 2 mg abicipar pegol every...
07:00 , Sep 7, 2015 |  BC Week In Review  |  Company News

Molecular Partners, Allergan deal

Molecular Partners will receive $35 million in accelerated milestone payments from Allergan Inc., now Allergan plc (NYSE:AGN, Dublin, Ireland), in connection with two ophthalmic deals. The companies partnered in May 2011 to develop and...
07:00 , Aug 10, 2015 |  BC Week In Review  |  Clinical News

Abicipar pegol: Phase III started

Allergan began the double-blind, sham-controlled, international Phase III SEQUOIA and CDER trials to compare 2 dosing schedules of 2 mg intravitreal abicipar pegol vs. Lucentis ranibizumab for 96 weeks each in about 900 patients....
01:34 , Mar 11, 2015 |  BC Extra  |  Company News

Molecular Partners CEO Zahnd to take medical leave

Molecular Partners AG (SIX:MOLN) said CEO Christian Zahnd will soon take temporary medical leave. In the interim, COO Patrick Amstutz and Chairman Jorn Aldag will take over Zahnd's responsibilities. Molecular Partners raised CHF98.6 million ($102.2...
03:15 , Nov 6, 2014 |  BC Extra  |  Financial News

IPO roundup: Xenon, Molecular Partners price; Inotek files

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) and Molecular Partners AG (SIX:MOLN) each priced IPOs and began trading, while Inotek Pharmaceuticals Corp. (Lexington, Mass.) filed for a new listing. Xenon gained $1.50 (17%) to $10.50 in its first...
02:15 , Nov 4, 2014 |  BC Extra  |  Financial News

Molecular Partners, Neuroderm set IPO terms

Molecular Partners AG (Schlieren, Switzerland) re-entered the IPO queue with a downsized offering on the SIX Swiss Exchange less than two weeks after postponing the listing due to market conditions, while NeuroDerm Ltd. (Rehovot, Israel)...
02:50 , Oct 23, 2014 |  BC Extra  |  Financial News

Molecular Partners postpones big Swiss IPO

Ophthalmic and cancer company Molecular Partners AG (Schlieren, Switzerland) postponed plans for a big IPO on the SIX Swiss Exchange, citing "adverse market conditions." The company had begun bookbuilding on Oct. 8 and was scheduled...